Targets › PTK2
4 programs from 4 companies in 32 trials: 15 Phase 2, 15 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.
Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. Required for early embryonic development and placenta development. (UniProt, Q05397)
Open in Phaseline: the race on PTK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Verastem | defactinib Focal adhesion kinase 1 inhibitor; Protein tyrosine kinase 2 beta inhibitor | PTK2, PTK2B | Phase 3 | Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation … | Dec 2026 |
| InxMed (Shanghai) | Ifebemtinib (IN10018) Focal adhesion kinase 1 inhibitor | PTK2 | Phase 3 | Non-Small Cell Lung Cancer; Ovarian Cancer Recurrent; Small Cell Lung Cancer Extensive Stage; Pancreatic Cancer … | Dec 2026 |
| Alliance for Clinical Trials in Oncology | FAK Inhibitor GSK2256098 Focal adhesion kinase (FAK) inhibitor | PTK2 | Phase 2 | Intracranial Meningioma | Jun 2028 |
| Amplia Therapeutics | AMP945 focal adhesion kinase (FAK) inhibitor | PTK2 | Phase 1 | Pancreatic Cancer | Feb 2027 |
Pancreatic Cancer (2) NSCLC (2) Low Grade Serous Ovarian Cancer (2) Non-Small Cell Lung Cancer (1) Ovarian Cancer Recurrent (1) Small Cell Lung Cancer Extensive Stage (1) Platinum-resistant Ovarian Cancer (1) Solid Tumor (1) Solid Tumor Cancer (1) Cervical Adenocarcinoma (1) Meningioma (1) Intracranial Meningioma (1)
small molecule (4)
InxMed (Shanghai) (1) Alliance for Clinical Trials in Oncology (1) Verastem (1) Amplia Therapeutics (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.